SEC Tracker
Get the app

Vir Biotechnology VIR

Vir Biotechnology appoints Suzanne Topalian

Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Board increased to nine members
  2. Dr. Topalian appointed as Class III director
  3. Received stock option and RSU (shares paid out over time) awards
  4. Indemnity agreement signed

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Vir Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  3. Immunome IMNM public float $729M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.